In a filing, Humacyte Inc revealed its Director Dougan Brady W unloaded Company’s shares for reported $1.79 million on Aug 19 ’25. In the deal valued at $1.63 per share,1,100,000 shares were sold. As a result of this transaction, Dougan Brady W now holds 591,685 shares worth roughly $1.04 million.
Then, Dougan Brady W sold 549,360 shares, generating $1,005,329 in total proceeds. Upon selling the shares at $1.83, the Director now owns 1,691,685 shares.
Before that, Dougan Brady W sold 591,685 shares. Humacyte Inc shares valued at $934,862 were divested by the Director at a price of $1.58 per share. As a result of the transaction, Dougan Brady W now holds 0 shares, worth roughly $0.0.
Barclays initiated its Humacyte Inc [HUMA] rating to an Overweight in a research note published on August 27, 2025; the price target was $3.50. H.C. Wainwright also remained covering HUMA and reiterated its “Buy” recommendation on December 20, 2024. H.C. Wainwright started covering the stock on December 11, 2023. It rated HUMA as “a Buy”.
Price Performance Review of HUMA
On Monday, Humacyte Inc [NASDAQ:HUMA] saw its stock jump 12.82% to $1.76. Over the last five days, the stock has lost -29.03%. Humacyte Inc shares have fallen nearly -67.32% since the year began. Nevertheless, the stocks have fallen -65.15% over the past one year.
How much short interest is there in Humacyte Inc?
A steep rise in short interest was recorded in Humacyte Inc stocks on 2025-09-30, dropping by -4.81 million shares to a total of 28.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 33.6 million shares. There was a decline of -16.7%, which implies that there is a negative sentiment for the stock.
